HYPERCALCEMIA TREATMENT MARKET ANALYSIS

Hypercalcemia Treatment Market, By Drug (Bisphosphonates, Calcimimetic Agents, Calcitonin, Glucocorticoids, Denusomab, Calcitonin, and Others), By Severity (Mild Hypercalcemia, Moderate Hypercalcemia, and Severe Hypercalcemia), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On August 12, 2024, Ascendis Pharma A/S, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved YORVIPATH (palopegteriparatide), previously known as TransCon PTH, for treating hypoparathyroidism in adults. YORVIPATH is a prodrug of parathyroid hormone (PTH[1-34]) administered once daily, designed to ensure continuous exposure to PTH throughout a 24-hour period. Hypoparathyroidism is a rare endocrine disorder characterized by inadequate levels of parathyroid hormone, which affects multiple organs.